Response to: 'Correspondence on 'Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab'' by Tampe et al .

We read with great interest the report by Tampe et al regarding their patient with granulomatosis with polyangiitis on rituximab who developed a serological response to SARS-CoV-2 and attenuated viral spread only after B cell reconstitution.1 This is an important observation, which is logical and further supports the recommendations to time the SARS-CoV-2 vaccine towards the end of the rituximab cycle and, if possible, to delay rituximab until 2–4 weeks after the second SARS-CoV-2 vaccination.2 3 While we agree with the …